Company intelligence / Profile preview
Biocytogen
Beijing, Beijing, Chinaen.biocytogen.com.cn ↗
- Ownership
- Public · 02315
- Development stage
- Phase 2
01
Overview
Biocytogen has developed a pipeline of at least ten core antibody assets. Lead programs such as YH001 (anti–CTLA–4) and YH002 (anti–OX40) have shown favorable safety/efficacy profiles in Phase I trials. The company’s proprietary platforms enable rapid generation of fully human antibodies against a wide range of targets. Multiple candidates are being evaluated alone or in combination therapies for solid tumors.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific/multispecific antibodiesNanobodiesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
52 assets51 more assets in the full pipeline.
Request access →03
Partnerships
SOTIO BiotechOna TherapeuticsAcepodiamultiple multinational pharmaceutical companies (>50 co-development/outlicensing agreements globally)
Beyond the preview
Go deeper on Biocytogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biocytogen.